Correction: Optomed Announces Clinical Trial Results

Optomed Plc         Inside Information              7 February 2022 at 15.50, Helsinki

Correction: Optomed Announces Clinical Trial Results

Optomed corrects a mistake that was in the clinical trial results release announced today 7 February 2022. The correct specificity was 93.6 percent instead of the 93.0 percent that was included in the original release.

The correct chapter:

Among patients positive for more-than-mild diabetic retinopathy, the combined product, Aurora AEYE detected 91.9 percent (sensitivity), while patients without the eye disease were correctly identified 93.6 percent of the time (specificity). The observed imageability was over 99 percent.

Optomed Plc

Further enquiries

Seppo Kopsala, CEO, seppo.kopsala@optomed.com

Optomed in Brief 

Optomed is a Finnish medical technology company and a leading manufacturer of handheld fundus cameras and screening software. Optomed combines handheld fundus cameras with software and artificial intelligence with the aim to transform the diagnostic process of various diseases, such as rapidly increasing diabetic retinopathy. Optomed has offices in Finland, the US and China and the company’s products are sold via various sales channels in over 60 countries globally

Disclaimer

CAUTION - Investigational device.  Limited by United States law to investigational use.